139 related articles for article (PubMed ID: 19691439)
1. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
2. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
Dobrzyn P; Dobrzyn A
Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
[TBL] [Abstract][Full Text] [Related]
3. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
5. An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 - 2013).
Powell DA
Expert Opin Ther Pat; 2014 Feb; 24(2):155-75. PubMed ID: 24251719
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
7. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
Ramtohul YK; Powell D; Leclerc JP; Leger S; Oballa R; Black C; Isabel E; Li CS; Crane S; Robichaud J; Guay J; Guiral S; Zhang L; Huang Z
Bioorg Med Chem Lett; 2011 Oct; 21(19):5692-6. PubMed ID: 21871798
[TBL] [Abstract][Full Text] [Related]
8. Azacycloalkane derivatives as inhibitors of delta-9 stearoyl-coenzyme A desaturase.
Liu G
Expert Opin Ther Pat; 2009 Jun; 19(6):885-91. PubMed ID: 19473107
[TBL] [Abstract][Full Text] [Related]
9. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease.
Zhang Z; Dales NA; Winther MD
J Med Chem; 2014 Jun; 57(12):5039-56. PubMed ID: 24295027
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
Zhao H; Serby MD; Smith HT; Cao N; Suhar TS; Surowy TK; Camp HS; Collins CA; Sham HL; Liu G
Bioorg Med Chem Lett; 2007 Jun; 17(12):3388-91. PubMed ID: 17434733
[TBL] [Abstract][Full Text] [Related]
13. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.
Tawa P; Falgueyret JP; Guiral S; Isabel E; Powell DA; Zuck P; Skorey K
J Biomol Screen; 2011 Jun; 16(5):506-17. PubMed ID: 21406617
[TBL] [Abstract][Full Text] [Related]
14. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
Li CS; Belair L; Guay J; Murgasva R; Sturkenboom W; Ramtohul YK; Zhang L; Huang Z
Bioorg Med Chem Lett; 2009 Sep; 19(17):5214-7. PubMed ID: 19632834
[TBL] [Abstract][Full Text] [Related]
15. Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1).
Voss MD; Zoller G; Matter H; Herling AW; Biemer-Daub G; Pfenninger A; Haag-Diergarten S; Keil S; Kohlmann M; Schmidts HL
Eur J Pharmacol; 2013 May; 707(1-3):140-6. PubMed ID: 23524088
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Liu G
Curr Top Med Chem; 2010; 10(4):419-33. PubMed ID: 20180759
[TBL] [Abstract][Full Text] [Related]
17. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
Roongta UV; Pabalan JG; Wang X; Ryseck RP; Fargnoli J; Henley BJ; Yang WP; Zhu J; Madireddi MT; Lawrence RM; Wong TW; Rupnow BA
Mol Cancer Res; 2011 Nov; 9(11):1551-61. PubMed ID: 21954435
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
Nishizawa S; Sumi H; Satoh Y; Yamamoto Y; Kitazawa S; Honda K; Araki H; Kakoi K; Imamura K; Sasaki M; Miyahisa I; Satomi Y; Nishigaki R; Hirayama M; Aoyama K; Maezaki H; Hara T
Eur J Pharmacol; 2017 Jul; 807():21-31. PubMed ID: 28442322
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Yamada M; Deguchi T; Konishi M; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2010 Nov; 45(11):4788-96. PubMed ID: 20801551
[TBL] [Abstract][Full Text] [Related]
20. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]